<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Health and Prostate &#187; Pharmacotherapy</title>
	<atom:link href="http://healthandprostate.com/category/pharmacotherapy/feed" rel="self" type="application/rss+xml" />
	<link>http://healthandprostate.com</link>
	<description>Benign Prostatic Hyperplasia - Prostate Cancer - Prostatitis</description>
	<lastBuildDate>Fri, 28 Oct 2011 14:09:19 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.1</generator>
<xhtml:meta xmlns:xhtml="http://www.w3.org/1999/xhtml" name="robots" content="noindex" />
		<item>
		<title>Immunotherapies for Prostate Cancer</title>
		<link>http://healthandprostate.com/pharmacotherapy/immunotherapies-for-prostate-cancer</link>
		<comments>http://healthandprostate.com/pharmacotherapy/immunotherapies-for-prostate-cancer#comments</comments>
		<pubDate>Mon, 19 Jul 2010 12:21:25 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Pharmacotherapy]]></category>
		<category><![CDATA[Conjugated]]></category>
		<category><![CDATA[Finasteride]]></category>
		<category><![CDATA[Retrovir]]></category>

		<guid isPermaLink="false">http://healthandprostate.com/?p=581</guid>
		<description><![CDATA[Prostate cancer is the second leading cause of death in men, with approximately 220,000 new cases and an expected 28,000 deaths in the year 2003. A decrease in prostate cancer related deaths has been attributed to early prostate-specific antigen (PSA) detection, more effective chemotherapy treatments, and immunotherapies. Although tumors can often evade an immune response by modulating their tumor antigens, reducing major histocompatibility complex-1 (MHC-I) expression or inhibiting cytotoxic T-cell activity, the use of immune modulation for prostate cancer is a relatively new concept because the prostate is not generally considered a site where immune processes typically occur. Since tumors arise when cancer cells evade the immune system, the prostate is an ideal target for immunotherapy The four most common types of lesions associated with the prostate are acute/chronic prostatitis (bacterial/abacterial), proliferative inflammatory atrophy (PIA), benign prostatic hyperplasia (BPH), and prostate carcinoma. The types of proliferative lesions that occur in the prostate are in different regions Read more [...]]]></description>
			<content:encoded><![CDATA[Prostate cancer is the second leading cause of death in men, with approximately 220,000 new cases and an expected 28,000 deaths in the year 2003. A decrease in prostate cancer related deaths has been attributed to early prostate-specific antigen (PSA) detection, more effective chemotherapy treatments, and immunotherapies. Although tumors can often evade an immune response by modulating their tumor antigens, reducing major histocompatibility complex-1 (MHC-I) expression or inhibiting cytotoxic T-cell activity, the use of immune modulation for prostate cancer is a relatively new concept because the prostate is not generally considered a site where immune processes typically occur. Since tumors arise when cancer cells evade the immune system, the prostate is an ideal target for immunotherapy

The four most common types of lesions associated with the prostate are acute/chronic prostatitis (bacterial/abacterial), proliferative inflammatory atrophy (PIA), benign prostatic hyperplasia (BPH), and prostate carcinoma. The types of proliferative lesions that occur in the prostate are in different regions <a href="http://healthandprostate.com/pharmacotherapy/immunotherapies-for-prostate-cancer" class="more-link">Read more [...]</a>]]></content:encoded>
			<wfw:commentRss>http://healthandprostate.com/pharmacotherapy/immunotherapies-for-prostate-cancer/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drugs for prostate cancer: Nilandron and Novantrone</title>
		<link>http://healthandprostate.com/pharmacotherapy/drugs-for-prostate-cancer-nilandron-and-novantrone</link>
		<comments>http://healthandprostate.com/pharmacotherapy/drugs-for-prostate-cancer-nilandron-and-novantrone#comments</comments>
		<pubDate>Wed, 10 Mar 2010 08:27:20 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Pharmacotherapy]]></category>
		<category><![CDATA[Flutamide]]></category>
		<category><![CDATA[Prednisone]]></category>

		<guid isPermaLink="false">http://healthandprostate.com/?p=429</guid>
		<description><![CDATA[In recent weeks, the FDA has approved two drugs for prostate cancer: Hoechst's antiandrogen nilutamide (Nilandron) for metastatic disease and Immunex' antineoplastic mitoxantrone (Novantrone) for hormone-resistant disease. Neither drug offers a cure for prostate cancer, but both delay disease progression and provide relief of bone pain. Nilutamide Nilutamide (Nilandron) is indicated for add-on therapy following surgical or chemical castration. The drug promotes disease regression, prolongs survival, and decreases bone pain. In one double-blind, randomized multicenter study comparing 225 castrated patients who received nilutamide and 232 castrated patients who received placebo, patients in the nilutamide group showed a longer progression-free survival (21.2 months in the nilutamide group versus 14.7 months in the placebo group), a longer median overall survival (27.3 months versus 23.6 months), and significant improvements in bone pain (54% versus 37%). Side effects, experienced by 86% of nilutamide patients, included hot flashes (28% incidence in treated patients and 22% in placebo patients) and Read more [...]]]></description>
			<content:encoded><![CDATA[In recent weeks, the FDA has approved two drugs for prostate cancer: Hoechst's antiandrogen nilutamide (Nilandron) for metastatic disease and Immunex' antineoplastic mitoxantrone (Novantrone) for hormone-resistant disease. Neither drug offers a cure for prostate cancer, but both delay disease progression and provide relief of bone pain.
Nilutamide
Nilutamide (Nilandron) is indicated for add-on therapy following surgical or chemical castration. The drug promotes disease regression, prolongs survival, and decreases bone pain. In one double-blind, randomized multicenter study comparing 225 castrated patients who received nilutamide and 232 castrated patients who received placebo, patients in the nilutamide group showed a longer progression-free survival (21.2 months in the nilutamide group versus 14.7 months in the placebo group), a longer median overall survival (27.3 months versus 23.6 months), and significant improvements in bone pain (54% versus 37%). Side effects, experienced by 86% of nilutamide patients, included hot flashes (28% incidence in treated patients and 22% in placebo patients) and <a href="http://healthandprostate.com/pharmacotherapy/drugs-for-prostate-cancer-nilandron-and-novantrone" class="more-link">Read more [...]</a>]]></content:encoded>
			<wfw:commentRss>http://healthandprostate.com/pharmacotherapy/drugs-for-prostate-cancer-nilandron-and-novantrone/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmacotherapy for BPH (Benign Prostatic Hyperplasia)</title>
		<link>http://healthandprostate.com/pharmacotherapy/pharmacotherapy-for-bph-benign-prostatic-hyperplasia</link>
		<comments>http://healthandprostate.com/pharmacotherapy/pharmacotherapy-for-bph-benign-prostatic-hyperplasia#comments</comments>
		<pubDate>Wed, 03 Mar 2010 21:45:48 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Pharmacotherapy]]></category>
		<category><![CDATA[Aldactone]]></category>
		<category><![CDATA[Bromocriptine]]></category>
		<category><![CDATA[Cardura]]></category>
		<category><![CDATA[Casodex]]></category>
		<category><![CDATA[Doxazosin]]></category>
		<category><![CDATA[Eulexin]]></category>
		<category><![CDATA[Finasteride]]></category>
		<category><![CDATA[Flutamide]]></category>
		<category><![CDATA[Hytrin]]></category>
		<category><![CDATA[Ketoconazole]]></category>
		<category><![CDATA[Minipress]]></category>
		<category><![CDATA[Nizoral]]></category>
		<category><![CDATA[Prazosin]]></category>
		<category><![CDATA[Proscar]]></category>
		<category><![CDATA[Spironolactone]]></category>
		<category><![CDATA[Tamoxifen]]></category>
		<category><![CDATA[Terazosin]]></category>

		<guid isPermaLink="false">http://healthandprostate.com/?p=421</guid>
		<description><![CDATA[Mechanisms of Obstruction and Rationale for Pharmacotherapy Current pharmacotherapy for Benign Prostatic Hyperplasia (BPH) is based on agents that relax the smooth muscles of prostatic urethra and stroma and those that deprive acinar cells of androgen. Various agents have been tried in the treatment of BPH (Table). They may be broadly grouped into those affecting the dynamic component of urethral obstruction, namely the smooth muscle and prostatic stroma, and those affecting the glandular elements by androgen deprivation. The mechanism of action of many agents claimed to be useful in Benign Prostatic Hyperplasia is not clearly understood. TABLE — Drugs That Have Been Tried in the Medical Management of Benign Prostatic Hyperplasia (Some agents act by more than one mechanism) Drug Class Drug (Code Designation) Trade Name α1-Adrenergic antagonists Prazosin HCl Minipress Terazosin HCl Hytrin Doxazosin mesylate Cardura Phentolamine mesylate YM-617 Nicergoline Sermion Indoramin Baratol Ketanserin Yohimbine HCI Antiandrogens Selective 5α-Reductase Read more [...]]]></description>
			<content:encoded><![CDATA[Mechanisms of Obstruction and Rationale for Pharmacotherapy
Current pharmacotherapy for Benign Prostatic Hyperplasia (BPH) is based on agents that relax the smooth muscles of prostatic urethra and stroma and those that deprive acinar cells of androgen.

Various agents have been tried in the treatment of BPH (Table). They may be broadly grouped into those affecting the dynamic component of urethral obstruction, namely the smooth muscle and prostatic stroma, and those affecting the glandular elements by androgen deprivation. The mechanism of action of many agents claimed to be useful in Benign Prostatic Hyperplasia is not clearly understood.



TABLE — Drugs That Have Been Tried in the    Medical Management of Benign Prostatic Hyperplasia
(Some agents act by more than one mechanism)


Drug Class
Drug (Code Designation)
Trade Name


α1-Adrenergic antagonists



Prazosin HCl
Minipress


Terazosin HCl
Hytrin


Doxazosin mesylate
Cardura


Phentolamine mesylate



YM-617



Nicergoline
Sermion


Indoramin
Baratol


Ketanserin



Yohimbine HCI



Antiandrogens


Selective


5α-Reductase <a href="http://healthandprostate.com/pharmacotherapy/pharmacotherapy-for-bph-benign-prostatic-hyperplasia" class="more-link">Read more [...]</a>]]></content:encoded>
			<wfw:commentRss>http://healthandprostate.com/pharmacotherapy/pharmacotherapy-for-bph-benign-prostatic-hyperplasia/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

